(Press-News.org) Highlights
Investigators have found demographic differences between participants of kidney transplant clinical trials and transplant recipients in the United States, even in recent years.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Investigators recently examined the extent to which participants in clinical trials related to kidney transplantation are similar to individuals undergoing transplantation in the United States. The research will be presented at ASN Kidney Week 2023 November 1–November 5.
The analysis included randomized controlled trials completed between 1990 to 2020 that included adult kidney transplant recipients, involved at least one U.S. center, and had 100 or more participants. For each trial, the inclusion and exclusion criteria were applied to the Scientific Registry of Transplant Recipients (SRTR) to identify patients undergoing transplantation during the trial enrollment period.
The investigators identified 43 trials that met the study inclusion criteria, with a total of 13,780 participants enrolled. After searching each trial’s inclusion and exclusion criteria during the trial enrollment period, 32,1779 transplant recipients were identified in the SRTR who were potentially eligible for trial participation.
Trial participants were younger, more likely to be White, and less likely to be Black or Asian. These differences between trial participants and transplant eligible transplant recipients in the U.S. persisted even in more recent trials.
“Concentrated efforts are ongoing to address the need for better participant diversity in clinical trials,” said corresponding author Oshorenua Aiyegbusi, MD, of the University of British Columbia, Division of Nephrology, Vancouver, Canada. “Improvement is still needed; our clinical trials should reflect our patients. Our work suggests we ought to review our clinical trial enrolment processes to identify barriers in participation for women and patients of diverse ethnic and racial groups.”
Study: “Representativeness of Randomized Control Trials in Kidney Transplantation”
The world's premier nephrology meeting, ASN Kidney Week, brings together approximately 12,000 kidney professionals from across the world. The largest nephrology meeting provides participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 21,000 members representing 140 countries. For more information, visit www.asn-online.org and follow us on Facebook, X, LinkedIn, and Instagram.
# # #
END
Highlights
In a recent analysis of US data, Black patients with kidney failure experienced survival advantages compared with White patients when county-level structural racism was low, but they experienced survival disadvantages compared with White patients at higher levels of structural racism.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — A new analysis indicates that county-level structural racism is a significant determinant of death among individuals ...
Highlights
Imaging tests in individuals with type 2 diabetes without symptoms of cardiovascular disease indicated that elevated albumin in the urine may be linked with sub-clinical coronary artery pathology, including coronary artery microcalcifications.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Advances in non-invasive imaging have allowed clinicians to assess both the structure and function of coronary arteries. Investigators who recently used positron emission tomography and computed tomography ...
Highlights
By examining the gene expression patterns of single cells from human fetal kidneys, researchers created a map that demonstrates the trajectories of cell states in the developing kidney and that identifies characteristics associated with kidney diseases.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Scientists have examined the gene expression patterns of single cells from 5 human fetal kidneys to create the most complete atlas of the ...
Highlights
Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes. An exploratory analysis ...
Alaskans and visitors may be able to see an artificial airglow in the sky created by the High-frequency Active Auroral Research Program during a four-day research campaign that starts Saturday.
Scientists from the University of Alaska Fairbanks, Cornell University, University of Colorado Denver, University of Florida and Georgia Institute of Technology will conduct a variety of experiments at the UAF-operated research site.
The experiments will focus on the ionosphere, the region of the atmosphere between about 30 and 350 miles ...
“The patient was managed with ripretinib and surgical resection of progressing lesions at multiple time points which led to extended clinical benefit.”
BUFFALO, NY- November 3, 2023 – A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.”
Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced ...
Health happens where people work, live, play and worship, says Prof. Stacey Snelling, chair of the Department of Health Studies in American University’s College of Arts and Sciences. And that’s where the Healthy Schools, Healthy Communities Lab engages children, adults and older adults to tackle health inequities. Snelling received a three-year grant of $2.8 million from Novo Nordisk Inc. for health education and to grow the number of Black farmers producing locally grown fruit and vegetables. The goal is to improve local ...
BOSTON – Ready or not, patients with cancer are increasingly likely to find themselves interacting with artificial intelligence technologies to schedule appointments, monitor their health, learn about their disease and its treatment, find support, and more. In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.
The authors note that while AI has immense potential for expanding access to cancer care and improving the ...
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity, according to a new study published on Nov. 2 in the Journal of Clinical Oncology.
The radiopharmaceutical 225AC-J591 was administered in a single injection and consists of two parts: an antibody that helps find the cancer cells is linked to a molecule that delivers a deadly dose of radiation. Specifically, an antibody named J591 that ...
MINNEAPOLIS/ST. PAUL (11/03/2023) — Research led by the University of Minnesota Medical School identified a new pathway to combat cardiovascular disease. The study was recently published in Nature Cardiovascular Research.
The research team’s work identifies a molecule called TREM2 as a unique and therapeutically relevant pathway for the treatment of atherosclerosis—a common condition that develops when plaque builds up inside arteries—in preclinical models. Atherosclerosis is a primary cause of cardiovascular diseases, which are the number one ...
